Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
about
Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer.PI3K mutations in breast cancer: prognostic and therapeutic implicationsOncogenic mutations of PIK3CA in human cancersIntegrated functional, gene expression and genomic analysis for the identification of cancer targetsThe evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismDeciphering the impact of somatic mutations in exon 20 and exon 9 of PIK3CA gene in breast tumors among Indian women through molecular dynamics approach.Rapamycin inhibits IGF-1-mediated up-regulation of MDM2 and sensitizes cancer cells to chemotherapyPI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancerA SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA geneDelineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines.The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma.Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.PI3K pathway activation results in low efficacy of both trastuzumab and lapatinibPIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method.Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancerst-DARPP regulates phosphatidylinositol-3-kinase-dependent cell growth in breast cancer.Activation of diverse signalling pathways by oncogenic PIK3CA mutations.Single nucleotide polymorphism rs17849071 G/T in the PIK3CA gene is inversely associated with follicular thyroid cancer and PIK3CA amplification.Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatmentRole of E542 and E545 missense mutations of PIK3CA in breast cancer: a comparative computational approach.An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancerA pathway-centric survey of somatic mutations in Chinese patients with colorectal carcinomasCorrelation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.Elevated PI3K signaling drives multiple breast cancer subtypes.Rare cancer-specific mutations in PIK3CA show gain of functionSomatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomasEverolimus restrains the paracrine pro-osteoclast activity of breast cancer cells.PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitorsReduced-representation Phosphosignatures Measured by Quantitative Targeted MS Capture Cellular States and Enable Large-scale Comparison of Drug-induced PhenotypesFeedbacks, Bifurcations, and Cell Fate Decision-Making in the p53 SystemPTEN insufficiency modulates ER+ breast cancer cell cycle progression and increases cell growth in vitro and in vivo.Optical painting and fluorescence activated sorting of single adherent cells labelled with photoswitchable Pdots.3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner.Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancerMutation of the PIK3CA oncogene in human cancersClinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer.
P2860
Q27851714-1EA41C5F-9673-4E22-80DF-93375E0AD4E1Q28081992-4F162A78-2B3E-49CF-A091-C79B5E06A5C1Q28284802-2DFFE909-C9C6-46C0-8925-44A76046EDBDQ28475254-A7D77BCF-03FB-45EA-AF49-5132926490ACQ29547302-0574DF31-625B-48F1-9A76-B9CD0F46FD3FQ30371703-CBD67A8B-E5BD-4577-91E2-5227AE1C1745Q30419679-45168D1A-F970-4950-8CB6-CBFE01F307E6Q33291674-EA237EE8-2F27-407A-A78B-CDA4EBCB3BCEQ33436440-ED2D4F97-EC5C-4F05-B58A-8B591BB05B92Q33532630-E6A68263-E81A-40AA-9405-B28CDC9AF76BQ33607950-29275159-1DF2-49AA-9024-4011DD25A1BCQ33674656-3F41E6E4-912D-41F4-9208-CF268EE9DA50Q33806957-E40DF674-D26F-4590-B645-E6AA84B7DBF1Q33933626-2AABA9A4-E1F7-4E0A-A146-42B0984BBB42Q34084868-F91C1B11-BF6D-416E-A39D-FBE1A7B619D0Q34122822-E3975021-51FE-44E7-BA26-8B79BC23127CQ34153121-DCCB4BE8-D0DA-4E2B-BAC7-346669DDD544Q34156895-8D615B86-940B-4EC1-9DDE-7EBF4D7B3FE9Q34408364-A0176C1B-4FCE-4A48-9D60-0C0489D76D4BQ34489924-9C0430DB-95D0-4CF0-BCF0-072C031517C5Q34508976-29CDEC05-4BEF-4026-9FA6-DC9B38801AEFQ34539092-9AECA1A1-6EA1-49AC-9D76-2D6E11AFD3B0Q34776985-0A77DD10-78D8-4C67-92A1-F855636CC163Q35009055-487B561A-6311-47D2-80D1-56D05CF958D3Q35223770-0F78F330-A2D8-48E6-A0E0-295869E781D7Q35562967-1D130EE6-466A-4F01-9BDB-33D83C770C43Q35640263-12DEF6C4-1973-4712-96A6-BD46CA2B1A80Q35720258-DBA77235-FC4F-4A85-AC4E-2AE0AC977824Q35749438-85797B25-D99A-42C2-AAE9-A7C7F100D208Q35807838-A61BFA73-3932-4227-A8D9-6832CCA13713Q35838565-7BC4C05C-C5B7-437D-B0D6-0372625BE87CQ35935148-47DFAAF4-C01E-4063-899B-D62CC6D28D9EQ35940296-E84D2F29-A080-4148-B645-62350222BBC3Q35970618-F833DC9A-C0AF-452F-B3F2-E67BC2875ABBQ36000357-E5F8585A-608D-475C-85DF-87AAE1793A72Q36200417-FA44792A-01B4-4FFF-9488-6667E300C9DEQ36245376-785C2CF8-255A-4BEA-A28F-29F81B7AA0B1Q36287691-7A483C11-DDB4-48A5-871F-363AA1DC9C8EQ36383360-D8F870F5-8608-4383-94B5-67B27625335DQ36458731-5F8138B0-5A8A-4AC6-9DF8-742DC2314CB5
P2860
Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Somatic mutation and gain of copy number of PIK3CA in human breast cancer
@nl
Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
@ast
Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
@en
type
label
Somatic mutation and gain of copy number of PIK3CA in human breast cancer
@nl
Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
@ast
Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
@en
prefLabel
Somatic mutation and gain of copy number of PIK3CA in human breast cancer
@nl
Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
@ast
Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
@en
P2093
P2860
P3181
P356
P1476
Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
@en
P2093
Aditi Chatterjee
Barry Trink
David Goldenberg
David Sidransky
Elizabeth Mambo
Junwei Liu
Mingzhao Xing
Saraswati Sukumar
Susanne M Gollin
P2860
P2888
P304
P3181
P356
10.1186/BCR1262
P407
P577
2005-05-31T00:00:00Z
P5875
P6179
1048306918